A&L Canada Laboratories to Lead Testing in Cannabis Traceability Program

Cannabis Investing News

A&L Canada Laboratories and TruTrace Technologies (CSE:TTT,OTC:TTTSF), announced Tuesday that A&L will be one of the inaugural testing facilities in the Shoppers Drug Mart and TruTrace Technologies medical cannabis verification pilot program. As quoted in the press release: As announced by Shoppers at the second annual World Cannabis Congress, the Pilot Program is built on TruTrace’s proprietary …

A&L Canada Laboratories and TruTrace Technologies (CSE:TTT,OTC:TTTSF), announced Tuesday that A&L will be one of the inaugural testing facilities in the Shoppers Drug Mart and TruTrace Technologies medical cannabis verification pilot program.

As quoted in the press release:

As announced by Shoppers at the second annual World Cannabis Congress, the Pilot Program is built on TruTrace’s proprietary StrainSecure™ platform, which focuses on testing and verification to confirm the origin, authenticity and quality assurance of cannabis products.

A&L was one of the earliest testing facilities to receive a Health Canada testing license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and provides a wide range of analytical services to the cannabis industry. A&L was recently presented the award for the Best Testing Facility at the 2019 O’Cannabiz Awards Gala – a national annual event honouring cannabis professionals and companies, recognizing excellence and innovation in the industry.

“We provide the full range of services required by TruTrace and Shoppers, and we are proud to support the transparency and accountability goals of this Pilot Program. Our capabilities in testing through all stages of the cannabis production cycle will fully support the quality assurance mandate of Shoppers,” said Nevin McDougall, President and Chief Commercial Officer of A&L.

“We are very pleased to have secured the support of A&L to provide an essential element of the Pilot Program,” said TruTrace Technologies CEO Robert Galarza. “A fundamental objective of the program is to provide complete assurance to medical patients about the origins and quality of their cannabis. A&L’s testing services are a key aspect of meeting that objective.”

Click here to read the full press release.

The Conversation (0)
×